| 0.846 | 0.003 | 0.846 | Bronchodilator | | |
| 0.722 | 0.005 | 0.722 | Spasmolytic | | |
| 0.706 | 0.004 | 0.706 | Antiadrenergic | | |
| 0.711 | 0.01 | 0.711 | Antiobesity | | |
| 0.704 | 0.004 | 0.704 | Adrenaline antagonist | | |
| 0.665 | 0.003 | 0.665 | Calcium channel L-type activator | | |
| 0.672 | 0.01 | 0.672 | Toll-Like receptor agonist | | |
| 0.668 | 0.011 | 0.668 | Toll-Like receptor 7 agonist | | |
| 0.661 | 0.018 | 0.661 | Cyclophilin D inhibitor | | |
| 0.645 | 0.011 | 0.645 | Vasodilator, peripheral | | |
| 0.613 | 0.007 | 0.613 | Vasodilator, coronary | | |
| 0.6 | 0.002 | 0.6 | Phenylalanine 4-hydroxylase inhibitor | | |
| 0.597 | 0.002 | 0.597 | Adrenaline agonist | | |
| 0.567 | 0.007 | 0.567 | Psychostimulant | | |
| 0.565 | 0.018 | 0.565 | 5 Hydroxytryptamine release stimulant | | |
| 0.537 | 0.002 | 0.537 | Beta 2 adrenoreceptor antagonist | | |
| 0.535 | 0.007 | 0.535 | Interleukin agonist | | |
| 0.522 | 0.002 | 0.522 | Beta adrenoreceptor antagonist | | |
| 0.552 | 0.037 | 0.552 | Transcription factor NF kappa B inhibitor | | |
| 0.52 | 0.008 | 0.52 | Peroxidase inhibitor | | |
| 0.522 | 0.029 | 0.522 | Cholesterol antagonist | | |
| 0.489 | 0.001 | 0.489 | Beta adrenoreceptor agonist | | |
| 0.491 | 0.005 | 0.491 | Calcium channel activator | | |
| 0.471 | 0.002 | 0.471 | Beta 1 adrenoreceptor antagonist | | |
| 0.456 | 0.002 | 0.456 | Beta 3 adrenoreceptor antagonist | | |
| 0.472 | 0.04 | 0.472 | Histamine release inhibitor | | |
| 0.453 | 0.037 | 0.453 | Antithrombotic | | |
| 0.412 | 0.006 | 0.412 | Peptidyltransferase inhibitor | | |
| 0.412 | 0.007 | 0.412 | Tyrosine 3 hydroxylase inhibitor | | |
| 0.409 | 0.006 | 0.409 | Insulin sensitizer | | |
| 0.426 | 0.024 | 0.426 | Cardiotonic | | |
| 0.424 | 0.025 | 0.424 | Free radical scavenger | | |
| 0.401 | 0.005 | 0.401 | Acetylcholine M1 receptor antagonist | | |
| 0.397 | 0.001 | 0.397 | Beta 1 adrenoreceptor agonist | | |
| 0.419 | 0.024 | 0.419 | Superoxide dismutase inhibitor | | |
| 0.421 | 0.031 | 0.421 | Antioxidant | | |
| 0.391 | 0.007 | 0.391 | Anesthetic local | | |
| 0.402 | 0.023 | 0.402 | Vasodilator | | |
| 0.432 | 0.06 | 0.432 | 5 Hydroxytryptamine release inhibitor | | |
| 0.384 | 0.027 | 0.384 | Amyloid beta aggregation inhibitor | | |
| 0.362 | 0.005 | 0.362 | Acetylcholine muscarinic antagonist | | |
| 0.353 | 0.001 | 0.353 | Beta 2 adrenoreceptor agonist | | |
| 0.356 | 0.004 | 0.356 | Acetylcholine M3 receptor antagonist | | |
| 0.382 | 0.033 | 0.382 | Interleukin 2 agonist | | |
| 0.358 | 0.01 | 0.358 | Cholinergic antagonist | | |
| 0.356 | 0.01 | 0.356 | Acetylcholine antagonist | | |
| 0.361 | 0.023 | 0.361 | 5 Hydroxytryptamine uptake stimulant | | |
| 0.399 | 0.062 | 0.399 | Calpain 2 inhibitor | | |
| 0.369 | 0.033 | 0.369 | Hypoglycemic | | |
| 0.366 | 0.031 | 0.366 | Sodium/bile acid cotransporter inhibitor | | |
| 0.332 | 0.002 | 0.332 | Adenylate cyclase stimulant | | |
| 0.338 | 0.017 | 0.338 | Melanin inhibitor | | |
| 0.334 | 0.015 | 0.334 | Monophenol monooxygenase inhibitor | | |
| 0.326 | 0.011 | 0.326 | Adenylate cyclase inhibitor | | |
| 0.353 | 0.044 | 0.353 | Hypoxia-inducible factor 1 alpha inhibitor | | |
| 0.359 | 0.053 | 0.359 | Aldehyde oxidase inhibitor | | |
| 0.378 | 0.073 | 0.378 | Immunosuppressant | | |
| 0.301 | 0.002 | 0.301 | Beta 3 adrenoreceptor agonist | | |
| 0.339 | 0.042 | 0.339 | Antiamyloidogenic | | |
| 0.359 | 0.062 | 0.359 | Immunostimulant | | |
| 0.309 | 0.017 | 0.309 | Phospholipase C inhibitor | | |
| 0.393 | 0.115 | 0.393 | Caspase 9 stimulant | | |
| 0.321 | 0.047 | 0.321 | Insulysin inhibitor | | |
| 0.315 | 0.044 | 0.315 | Hypolipemic | | |
| 0.29 | 0.021 | 0.29 | Neurotrophic factor enhancer | | |
| 0.281 | 0.015 | 0.281 | M18 aspartyl aminopeptidase inhibitor | | |
| 0.268 | 0.004 | 0.268 | Glutamate decarboxylase inhibitor | | |
| 0.294 | 0.033 | 0.294 | Calpain inhibitor | | |
| 0.29 | 0.034 | 0.29 | Growth hormone agonist | | |
| 0.269 | 0.022 | 0.269 | Nitric-oxide synthase stimulant | | |
| 0.25 | 0.012 | 0.25 | Carbonic anhydrase XV inhibitor | | |
| 0.249 | 0.012 | 0.249 | Neurotrophic factor | | |
| 0.253 | 0.017 | 0.253 | Cholesterol synthesis inhibitor | | |
| 0.244 | 0.014 | 0.244 | Interleukin 4 antagonist | | |
| 0.334 | 0.109 | 0.334 | 15-Lipoxygenase inhibitor | | |
| 0.24 | 0.026 | 0.24 | Phospholipase A2 inhibitor | | |
| 0.223 | 0.009 | 0.223 | Mucolytic | | |
| 0.267 | 0.056 | 0.267 | Cyclic AMP phosphodiesterase inhibitor | | |
| 0.217 | 0.007 | 0.217 | Alpha adrenoreceptor agonist | | |
| 0.326 | 0.117 | 0.326 | Antibacterial | | |
| 0.264 | 0.057 | 0.264 | Interleukin antagonist | | |
| 0.211 | 0.005 | 0.211 | Sphingosine 1-phosphate receptor 2 antagonist | | |
| 0.22 | 0.017 | 0.22 | Expectorant | | |
| 0.219 | 0.02 | 0.219 | Alpha 2b adrenoreceptor antagonist | | |
| 0.249 | 0.051 | 0.249 | Anesthetic general | | |
| 0.26 | 0.066 | 0.26 | Angiogenesis stimulant | | |
| 0.217 | 0.023 | 0.217 | DNA polymerase I inhibitor | | |
| 0.203 | 0.01 | 0.203 | Aminoacyl-tRNA synthetase inhibitor | | |
| 0.199 | 0.008 | 0.199 | Electron transport complex I inhibitor | | |
| 0.2 | 0.009 | 0.2 | NMDA 2 receptor antagonist | | |
| 0.215 | 0.029 | 0.215 | Insulin secretagoues | | |
| 0.219 | 0.034 | 0.219 | Lipid peroxidase inhibitor | | |
| 0.205 | 0.021 | 0.205 | Toll-Like receptor 2 antagonist | | |
| 0.197 | 0.015 | 0.197 | NMDA receptor antagonist | | |
| 0.28 | 0.1 | 0.28 | Apoptosis antagonist | | |
| 0.185 | 0.005 | 0.185 | Acetylcholine M5 receptor antagonist | | |
| 0.216 | 0.036 | 0.216 | Protein kinase stimulant | | |
| 0.179 | 0.009 | 0.179 | Carbonic anhydrase stimulant | | |
| 0.195 | 0.026 | 0.195 | Cystathionine beta-synthase inhibitor | | |
| 0.21 | 0.041 | 0.21 | Amylase inhibitor | | |
| 0.174 | 0.005 | 0.174 | NMDA 2A receptor antagonist | | |
| 0.222 | 0.057 | 0.222 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | | |
| 0.18 | 0.018 | 0.18 | Vanilloid 1 agonist | | |
| 0.244 | 0.084 | 0.244 | DNA damaging | | |
| 0.169 | 0.01 | 0.169 | Anabolic | | |
| 0.187 | 0.03 | 0.187 | Alkylator | | |
| 0.182 | 0.026 | 0.182 | Cyclooxygenase 3 inhibitor | | |
| 0.168 | 0.013 | 0.168 | Dopamine agonist | | |
| 0.159 | 0.01 | 0.159 | Acetylcholine M2 receptor antagonist | | |
| 0.158 | 0.009 | 0.158 | Amidase inhibitor | | |
| 0.178 | 0.029 | 0.178 | Antibacterial (Helicobacter pylori) | | |
| 0.155 | 0.01 | 0.155 | Ornithine decarboxylase inhibitor | | |
| 0.164 | 0.019 | 0.164 | Sphingomyelinase inhibitor | | |
| 0.164 | 0.021 | 0.164 | HIV-1 integrase (Overall Integration) inhibitor | | |
| 0.186 | 0.044 | 0.186 | Neurotensin receptor agonist | | |
| 0.276 | 0.133 | 0.276 | GABA C receptor rho-3 antagonist | | |
| 0.171 | 0.03 | 0.171 | Chelator | | |
| 0.145 | 0.005 | 0.145 | Oleamide hydrolase inhibitor | | |
| 0.158 | 0.019 | 0.158 | Carbonic anhydrase VI inhibitor | | |
| 0.156 | 0.018 | 0.156 | DOPA decarboxylase inhibitor | | |
| 0.162 | 0.027 | 0.162 | Alpha 2c adrenoreceptor antagonist | | |
| 0.157 | 0.024 | 0.157 | Gastric antisecretory | | |
| 0.229 | 0.098 | 0.229 | 5 Hydroxytryptamine 1E antagonist | | |
| 0.197 | 0.066 | 0.197 | P-glycoprotein inhibitor | | |
| 0.161 | 0.03 | 0.161 | GABA C receptor agonist | | |
| 0.135 | 0.005 | 0.135 | GABA B receptor agonist | | |
| 0.238 | 0.108 | 0.238 | Lipoxygenase inhibitor | | |
| 0.153 | 0.027 | 0.153 | Mediator release inhibitor | | |
| 0.14 | 0.016 | 0.14 | Somatostatin 1 agonist | | |
| 0.215 | 0.091 | 0.215 | Platelet antagonist | | |
| 0.158 | 0.036 | 0.158 | Alpha adrenoreceptor antagonist | | |
| 0.15 | 0.028 | 0.15 | Carbonic anhydrase III inhibitor | | |
| 0.191 | 0.071 | 0.191 | Nitric oxide antagonist | | |
| 0.151 | 0.033 | 0.151 | Nav1.4 sodium channel blocker | | |
| 0.131 | 0.014 | 0.131 | Interferon agonist | | |
| 0.142 | 0.026 | 0.142 | Prolactin inhibitor | | |
| 0.13 | 0.014 | 0.13 | Vanilloid agonist | | |
| 0.124 | 0.009 | 0.124 | Maillard reaction inhibitor | | |
| 0.16 | 0.046 | 0.16 | Sphingosine 1-phosphate receptor 5 antagonist | | |
| 0.13 | 0.018 | 0.13 | Phosphodiesterase 6D inhibitor | | |
| 0.145 | 0.034 | 0.145 | Photosensitizer | | |
| 0.149 | 0.038 | 0.149 | Aminopeptidase B inhibitor | | |
| 0.119 | 0.009 | 0.119 | Dopamine D2 agonist | | |
| 0.178 | 0.07 | 0.178 | Succinate dehydrogenase inhibitor | | |
| 0.153 | 0.045 | 0.153 | Proteasome inhibitor | | |
| 0.136 | 0.029 | 0.136 | Nitric-oxide synthase inhibitor | | |
| 0.119 | 0.013 | 0.119 | Alpha 1 adrenoreceptor agonist | | |
| 0.166 | 0.061 | 0.166 | Interferon gamma antagonist | | |
| 0.123 | 0.019 | 0.123 | Histamine H2 receptor antagonist | | |
| 0.135 | 0.032 | 0.135 | Estrogen antagonist | | |
| 0.111 | 0.014 | 0.111 | Estrogen-related receptor beta agonist | | |
| 0.104 | 0.007 | 0.104 | Sphingosine 1-phosphate receptor 3 antagonist | | |
| 0.107 | 0.01 | 0.107 | Interferon inducer | | |
| 0.117 | 0.021 | 0.117 | Myeloperoxidase inhibitor | | |
| 0.101 | 0.007 | 0.101 | Sphingosine kinase 2 inhibitor | | |
| 0.155 | 0.062 | 0.155 | Hemostatic | | |
| 0.111 | 0.02 | 0.111 | GABA aminotransferase inhibitor | | |
| 0.134 | 0.044 | 0.134 | TRPA1 agonist | | |
| 0.126 | 0.039 | 0.126 | Urease inhibitor | | |
| 0.109 | 0.023 | 0.109 | Aminopeptidase I inhibitor | | |
| 0.099 | 0.015 | 0.099 | Alpha 2 adrenoreceptor agonist | | |
| 0.129 | 0.046 | 0.129 | Transcription factor STAT6 inhibitor | | |
| 0.139 | 0.056 | 0.139 | Nav1.3 sodium channel blocker | | |
| 0.116 | 0.034 | 0.116 | Lanosterol 14 alpha demethylase inhibitor | | |
| 0.105 | 0.023 | 0.105 | Sphingosine 1-phosphate receptor 4 agonist | | |
| 0.145 | 0.063 | 0.145 | Bone formation stimulant | | |
| 0.158 | 0.076 | 0.158 | Thrombolytic | | |
| 0.116 | 0.036 | 0.116 | Estrogen receptor beta antagonist | | |
| 0.107 | 0.029 | 0.107 | Histidine decarboxylase inhibitor | | |
| 0.087 | 0.01 | 0.087 | Epithelial sodium channel blocker | | |
| 0.118 | 0.042 | 0.118 | Creatine kinase inhibitor | | |
| 0.087 | 0.012 | 0.087 | Sphingosine kinase inhibitor | | |
| 0.108 | 0.033 | 0.108 | Interleukin 5 antagonist | | |
| 0.138 | 0.065 | 0.138 | Nav1.2 sodium channel blocker | | |
| 0.107 | 0.035 | 0.107 | Bile acid receptor antagonist | | |
| 0.112 | 0.04 | 0.112 | Calcium antagonist | | |
| 0.123 | 0.05 | 0.123 | Protein kinase C gamma inhibitor | | |
| 0.079 | 0.009 | 0.079 | Mannosidase inhibitor | | |
| 0.079 | 0.01 | 0.079 | Vanilloid 2 antagonist | | |
| 0.111 | 0.042 | 0.111 | Glutamate (mGluR7) agonist | | |
| 0.164 | 0.095 | 0.164 | Hepatoprotectant | | |
| 0.103 | 0.034 | 0.103 | Inducible nitric-oxide synthase inhibitor | | |
| 0.196 | 0.129 | 0.196 | DNA synthesis inhibitor | | |
| 0.078 | 0.012 | 0.078 | Alpha-mannosidase inhibitor | | |
| 0.12 | 0.054 | 0.12 | Nav1.5 sodium channel blocker | | |
| 0.073 | 0.008 | 0.073 | Dopamine D5 agonist | | |
| 0.115 | 0.05 | 0.115 | Butyrylcholinesterase inhibitor | | |
| 0.208 | 0.143 | 0.208 | 12-Lipoxygenase inhibitor | | |
| 0.099 | 0.035 | 0.099 | Alpha 1b adrenoreceptor antagonist | | |
| 0.136 | 0.072 | 0.136 | Farnesoid X receptor antagonist | | |
| 0.263 | 0.201 | 0.263 | Apoptosis agonist | | |
| 0.079 | 0.018 | 0.079 | Glycine transporter 2 inhibitor | | |
| 0.065 | 0.005 | 0.065 | Calcium-sensing receptor antagonist | | |
| 0.105 | 0.045 | 0.105 | Alpha 2 adrenoreceptor antagonist | | |
| 0.099 | 0.04 | 0.099 | Topoisomerase II alpha inhibitor | | |
| 0.103 | 0.045 | 0.103 | Triose-phosphate isomerase inhibitor | | |
| 0.149 | 0.091 | 0.149 | Interleukin 6 antagonist | | |
| 0.114 | 0.058 | 0.114 | Ferrochelatase inhibitor | | |
| 0.133 | 0.077 | 0.133 | Histone deacetylase SIRT1 inhibitor | | |
| 0.085 | 0.029 | 0.085 | Leukotriene antagonist | | |
| 0.091 | 0.035 | 0.091 | Estrogen receptor alpha antagonist | | |
| 0.094 | 0.039 | 0.094 | Alpha 2a adrenoreceptor antagonist | | |
| 0.071 | 0.017 | 0.071 | Sphingosine 1-phosphate receptor 1 antagonist | | |
| 0.063 | 0.009 | 0.063 | Alpha 1d adrenoreceptor agonist | | |
| 0.073 | 0.02 | 0.073 | Glucosylceramidase inhibitor | | |
| 0.065 | 0.015 | 0.065 | NMDA receptor subunit 3A antagonist | | |
| 0.095 | 0.045 | 0.095 | Alpha 1 adrenoreceptor antagonist | | |
| 0.075 | 0.025 | 0.075 | Carbonic anhydrase VB inhibitor | | |
| 0.085 | 0.036 | 0.085 | Sphingosine 1-phosphate receptor antagonist | | |
| 0.061 | 0.014 | 0.061 | Dopamine beta hydroxylase inhibitor | | |
| 0.189 | 0.141 | 0.189 | Neuropeptide Y2 antagonist | | |
| 0.076 | 0.029 | 0.076 | Neuraminidase (influenza) inhibitor | | |
| 0.068 | 0.021 | 0.068 | Leukotriene B4 antagonist | | |
| 0.085 | 0.04 | 0.085 | Cathepsin G inhibitor | | |
| 0.084 | 0.039 | 0.084 | Lipase inhibitor | | |
| 0.122 | 0.077 | 0.122 | Papain-like protease (SARS coronavirus) inhibitor | | |
| 0.13 | 0.086 | 0.13 | Cell wall synthesis inhibitor | | |
| 0.069 | 0.026 | 0.069 | NMDA 2B receptor antagonist | | |
| 0.089 | 0.046 | 0.089 | Acetylcholine nicotinic antagonist | | |
| 0.079 | 0.036 | 0.079 | Carbonic anhydrase V inhibitor | | |
| 0.12 | 0.077 | 0.12 | Alpha-N-acetylglucosaminidase inhibitor | | |
| 0.052 | 0.009 | 0.052 | Sigma 2 receptor antagonist | | |
| 0.057 | 0.015 | 0.057 | Dopamine D3 agonist | | |
| 0.118 | 0.076 | 0.118 | Sphingosine 1-phosphate receptor 4 antagonist | | |
| 0.106 | 0.064 | 0.106 | Falcipain 3 inhibitor | | |
| 0.066 | 0.024 | 0.066 | Thromboxane A2 antagonist | | |
| 0.05 | 0.009 | 0.05 | Lysophosphatidic acid 2 receptor antagonist | | |
| 0.079 | 0.038 | 0.079 | Carbonic anhydrase VA inhibitor | | |
| 0.089 | 0.049 | 0.089 | Glutathione S-transferase inhibitor | | |
| 0.135 | 0.096 | 0.135 | Heat shock protein 70 antagonist | | |
| 0.071 | 0.032 | 0.071 | NMDA 2C receptor antagonist | | |
| 0.051 | 0.012 | 0.051 | Heme oxygenase inhibitor | | |
| 0.071 | 0.033 | 0.071 | Neuraminidase inhibitor | | |
| 0.055 | 0.017 | 0.055 | Histamine H2 receptor agonist | | |
| 0.043 | 0.006 | 0.043 | Alpha 1a adrenoreceptor agonist | | |
| 0.051 | 0.014 | 0.051 | Diamine oxidase inhibitor | | |
| 0.102 | 0.065 | 0.102 | Factor V inhibitor | | |
| 0.065 | 0.029 | 0.065 | Thromboxane antagonist | | |
| 0.069 | 0.033 | 0.069 | Prostaglandin EP2 antagonist | | |
| 0.061 | 0.025 | 0.061 | Thromboxane synthase inhibitor | | |
| 0.039 | 0.004 | 0.039 | Acid ceramidase inhibitor | | |
| 0.054 | 0.019 | 0.054 | Geranyltranstransferase inhibitor | | |
| 0.057 | 0.023 | 0.057 | Alpha 1b adrenoreceptor agonist | | |
| 0.045 | 0.011 | 0.045 | Catechol O-methyltransferase inhibitor | | |
| 0.049 | 0.016 | 0.049 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | | |
| 0.052 | 0.019 | 0.052 | Somatostatin 1 antagonist | | |
| 0.067 | 0.035 | 0.067 | Prostaglandin F2 alpha antagonist | | |
| 0.049 | 0.017 | 0.049 | Sphingosine kinase 1 inhibitor | | |
| 0.036 | 0.004 | 0.036 | Ileal bile acid transport inhibitor | | |
| 0.054 | 0.022 | 0.054 | NMDA receptor subunit 3B antagonist | | |
| 0.035 | 0.005 | 0.035 | Vanilloid 2 agonist | | |
| 0.047 | 0.017 | 0.047 | Sphingosine 1-phosphate receptor 3 agonist | | |
| 0.05 | 0.02 | 0.05 | Sphingosine 1-phosphate receptor 1 agonist | | |
| 0.034 | 0.005 | 0.034 | Alpha 2a adrenoreceptor agonist | | |
| 0.087 | 0.059 | 0.087 | Histamine N-methyltransferase inhibitor | | |
| 0.035 | 0.007 | 0.035 | 1,3-Beta-glucan synthase inhibitor | | |
| 0.068 | 0.04 | 0.068 | HIV-1 integrase (3'-Processing) inhibitor | | |
| 0.079 | 0.05 | 0.079 | Keratolytic | | |
| 0.057 | 0.029 | 0.057 | Sigma receptor antagonist | | |
| 0.047 | 0.02 | 0.047 | Plasmepsin II inhibitor | | |
| 0.055 | 0.029 | 0.055 | Lysophosphatidic acid 3 receptor antagonist | | |
| 0.045 | 0.019 | 0.045 | Estrogen receptor alpha agonist | | |
| 0.06 | 0.037 | 0.06 | Botulinum neurotoxin type A inhibitor | | |
| 0.058 | 0.035 | 0.058 | Leukotriene C antagonist | | |
| 0.104 | 0.082 | 0.104 | Topoisomerase II inhibitor | | |
| 0.091 | 0.071 | 0.091 | 5-Lipoxygenase inhibitor | | |
| 0.096 | 0.075 | 0.096 | Adenylate kinase inhibitor | | |
| 0.075 | 0.054 | 0.075 | Carbonic anhydrase XIII inhibitor | | |
| 0.075 | 0.055 | 0.075 | Na+ K+ transporting ATPase inhibitor | | |
| 0.031 | 0.01 | 0.031 | Sodium/glucose cotransporter inhibitor | | |
| 0.131 | 0.112 | 0.131 | Ca2+-transporting ATPase inhibitor | | |
| 0.063 | 0.043 | 0.063 | NMDA receptor agonist | | |
| 0.031 | 0.012 | 0.031 | Sodium/glucose cotransporter 2 inhibitor | | |
| 0.035 | 0.017 | 0.035 | Prostaglandin D2 agonist | | |
| 0.03 | 0.012 | 0.03 | Thyroid hormone agonist | | |
| 0.039 | 0.021 | 0.039 | Phosphoglycerate kinase inhibitor | | |
| 0.059 | 0.041 | 0.059 | Alpha 1d adrenoreceptor antagonist | | |
| 0.033 | 0.015 | 0.033 | Sigma 1 receptor antagonist | | |
| 0.036 | 0.019 | 0.036 | Calcium-independent phospholipase A2 inhibitor | | |
| 0.125 | 0.108 | 0.125 | Sigma receptor agonist | | |
| 0.034 | 0.017 | 0.034 | Glucagon receptor antagonist | | |
| 0.071 | 0.055 | 0.071 | CDC25A inhibitor | | |
| 0.05 | 0.034 | 0.05 | Squalene epoxidase inhibitor | | |
| 0.043 | 0.028 | 0.043 | Growth hormone release inhibitor | | |
| 0.124 | 0.108 | 0.124 | NOS3 expression enhancer | | |
| 0.038 | 0.024 | 0.038 | Arginase inhibitor | | |
| 0.022 | 0.008 | 0.022 | Estrogen-related receptor gamma agonist | | |
| 0.045 | 0.03 | 0.045 | Sphingosine 1-phosphate receptor agonist | | |
| 0.027 | 0.013 | 0.027 | Prostaglandin EP2 agonist | | |
| 0.027 | 0.014 | 0.027 | Lysophosphatidic acid receptor 1 agonist | | |
| 0.085 | 0.072 | 0.085 | Alcohol dehydrogenase inhibitor | | |
| 0.03 | 0.017 | 0.03 | Purinergic P2Y15 antagonist | | |
| 0.043 | 0.029 | 0.043 | Oxytocin agonist | | |
| 0.036 | 0.023 | 0.036 | Ceramide glucosyltransferase inhibitor | | |
| 0.193 | 0.18 | 0.193 | Caspase 3 stimulant | | |
| 0.081 | 0.068 | 0.081 | Opioid antagonist | | |
| 0.025 | 0.013 | 0.025 | Prostaglandin F2 alpha agonist | | |
| 0.047 | 0.036 | 0.047 | Carbonic anhydrase XIV inhibitor | | |
| 0.073 | 0.062 | 0.073 | Macrophage migration inhibitory factor inhibitor | | |
| 0.043 | 0.032 | 0.043 | Stearoyl-CoA desaturase inhibitor | | |
| 0.023 | 0.012 | 0.023 | Lysophosphatidic acid 1 receptor antagonist | | |
| 0.064 | 0.054 | 0.064 | Alpha 1a adrenoreceptor antagonist | | |
| 0.046 | 0.036 | 0.046 | Cholesterol esterase inhibitor | | |
| 0.126 | 0.117 | 0.126 | Arachidonic acid antagonist | | |
| 0.047 | 0.037 | 0.047 | Estrogen agonist | | |
| 0.108 | 0.099 | 0.108 | NADPH oxidase inhibitor | | |
| 0.058 | 0.051 | 0.058 | Dopamine D2 antagonist | | |
| 0.03 | 0.023 | 0.03 | Somatostatin 5 antagonist | | |
| 0.03 | 0.023 | 0.03 | Prostaglandin agonist | | |
| 0.026 | 0.021 | 0.026 | Leukotriene B4 receptor 1 antagonist | | |
| 0.057 | 0.052 | 0.057 | Selectin antagonist | | |
| 0.021 | 0.015 | 0.021 | Neuraminidase (Influenza B) inhibitor | | |
| 0.011 | 0.007 | 0.011 | Thromboxane agonist | | |
| 0.05 | 0.046 | 0.05 | Sphingosine 1-phosphate receptor 5 agonist | | |
| 0.055 | 0.05 | 0.055 | Opioid delta receptor antagonist | | |
| 0.06 | 0.056 | 0.06 | Phosphofructokinase-1 inhibitor | | |
| 0.036 | 0.032 | 0.036 | Membrane dipeptidase inhibitor | | |
| 0.056 | 0.053 | 0.056 | Enoyl-[acyl-carrier-protein] reductase inhibitor | | |
| 0.022 | 0.019 | 0.022 | Somatostatin 4 antagonist | | |
| 0.045 | 0.042 | 0.045 | Bombesin 2 receptor antagonist | | |
| 0.021 | 0.018 | 0.021 | Dopamine D1 agonist | | |
| 0.042 | 0.039 | 0.042 | Potassium channel Kv1.3 blocker | | |
| 0.054 | 0.053 | 0.054 | Purinergic P2X1 antagonist | | |
| 0.063 | 0.061 | 0.063 | HIV-1 integrase inhibitor | | |
| 0.045 | 0.044 | 0.045 | Ornithine carbamoyltransferase inhibitor | | |